Contribute Try STAT+ Today

Amid rising concern over the quality of the pharmaceutical supply chain, a government report finds that the number of domestic and foreign plant inspections conducted by the Food and Drug Administration declined from 2016 through 2018, partly due to a dearth of available inspectors.

Specifically, domestic inspections decreased by 13% and foreign inspections fell by 13% during that two-year period, although the number of foreign inspections exceeded domestic inspections in 2015. But while the FDA had 190 inspectors in the U.S. who conducted most foreign inspections, another 58 positions were vacant, according to a preliminary analysis by the U.S. Government Accountability Office.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This GAO report regurgitates the same data about what percentage of our “American” drugs are foreign made. It states: “FDA has estimated that about 40 percent of finished drugs and 80 percent of active drug ingredients are
    manufactured overseas.” According to our research from last year, 71 of 100 top brand name drugs, as in finished drugs, were foreign made:

    As we consider importation, getting our facts straight about what percent of our drug supply is already imported should be a priority.

    Gabriel Levitt

  • Janet was specifically asked (twice) about using external contractors to supplement the foreign inspection staff. Both times she declined to even directly address the question. For some reason, even though the FDA is struggling to hire inspectors, retain inspectors, and train inspectors, there is no plan to use outside contractors to conduct inspections. It boggles the mind.

Comments are closed.